( A recent meta-analysis reported comparing each strategy of combo therapy with the up-titration of basal insulin, showing no significant difference between the two approaches in HbA1c change, target HbA1c achievement rate, hypoglycemic risk, and body weight change ( Meanwhile, GLP-1RAs combined with each of the two FRC products show different temporal actions despite the same dosing frequency: lixisenatide of IGlarLixi is a short-acting agent, while liraglutide of IDegLira is a long-acting agent
Arthritis Res Ther (2015) 17:302
Papapetrou PD, MacSween RNM, Lazarus JH, Harden R McG
India could have over 440 million overweight or obese people by 2050, a study published in The Lancet showed
This opportunity is likely to be shared among 10-15 players, comprising Indian and global generic manufacturers, the report said